intratect 100 g/l inf. sol. i.v. vial
biotest pharma gmbh - human plasma proteins 100 mg/ml - solution for infusion - immunoglobulins, normal human, for intravascular adm.
intratect 100 g/l inf. sol. i.v. vial
biotest pharma gmbh - human plasma proteins 100 mg/ml - solution for infusion - immunoglobulins, normal human, for intravascular adm.
intratect 100 g/l inf. sol. i.v. vial
biotest pharma gmbh - human plasma proteins 100 mg/ml - solution for infusion - immunoglobulins, normal human, for intravascular adm.
intratect 50 g/l inf. sol. i.v. vial
biotest pharma gmbh - human plasma proteins 50 mg/ml - solution for infusion - immunoglobulins, normal human, for intravascular adm.
intratect 50 g/l inf. sol. i.v. vial
biotest pharma gmbh - human plasma proteins 50 mg/ml - solution for infusion - immunoglobulins, normal human, for intravascular adm.
intratect 50 g/l inf. sol. i.v. vial
biotest pharma gmbh - human plasma proteins 50 mg/ml - solution for infusion - immunoglobulins, normal human, for intravascular adm.
albiomin 20 %
kamada ltd, israel - plasma protein fraction - solution for infusion - plasma protein fraction 200 mg/ml - protein c - protein c - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendation.
human albumin 20% biotest 20g /100 ml infusion
gulf drug llc germany - 100ml vial - infusion - 20g /100 ml - nutrition , blood-fluids , electrolytes
human albumin 5% biotest 5 gm / 100ml infusion
gulf drug llc germany - 250 ml vial - infusion - 5 gm / 100ml - nutrition , blood-fluids , electrolytes
intratect 50 gl
kamada ltd, israel - human normal immunoglobulin - solution for infusion - human normal immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents (0-18 years) in:- primary immunodeficiency syndromes (pid) with impaired antibody production- secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of <4 g/l* psaf= failure to mount at least a 2-fold rise in igg antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccinesimmunomodulation in adults, and children and adolescents (0-18 years) in:- primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count- guillain barré syndrome- kawasaki disease (in conjunction with acetylsalicylic acid)- chronic inflammatory demyelinating polyradiculoneuropathy (cidp)- multifocal motor neuropathy (mmn)